Impact Factor 2024: 5.2 - Q1 (ONCOLOGY); CiteScore 2024: 8.3 - Q1 Pharmacology(medical). Indexed in PubMed Central(PMC), ESCI and Scopus #Cancer #DrugResistance
Joined September 2020
- Tweets 1,588
- Following 2,991
- Followers 865
- Likes 991
1,177 Photos and videos
Pinned Tweet
#CiteScore 2025: 10.3!
✅ 24% year-over-year
✅ #20 in Pharmacology worldwide (Top 8%)
✅ Cancer Research advances from Q2 to Q1
Thank you to our global community for helping advance the science of cancer drug resistance. 👉oaepublish.com/news/cdr.1516
#CancerResearch #Oncology
2
3
55
👏New in #Cancer #DrugResistance: #UGT1A1/2B7 drive chemoresistance to SN‑38, etoposide & epirubicin.
#TKIs like nilotinib and regorafenib act as dual‑activity modulators to reverse resistance
👀oaepublish.com/articles/cdr.…
20
👏The review how fenretinide nanoformulations overcome poor bioavailability to induce tumor dormancy and target cancer stem cells in #Cancer #DrugResistance!
#Fenretinide, 4-HPR, tumor dormancy, nanoformulations, #chemoprevention, cancer stem cells
👀oaepublish.com/articles/cdr.…
1
2
72
👏Excited to share a review in #Cancer #DrugResistance on overcoming anti-PD-1/PD-L1 resistance.
Title: Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer
Programmed cell death protein 1, programmed cell death ligand 1, drug resistance
👀oaepublish.com/articles/cdr.…
1
1
26
✍️The new study in #Cancer #DrugResistance shows that deleting #TRAP1 in #PDAC CSCs.
🙌Cancer stem cells, pancreatic ductal adenocarcinoma, TRAP1, #CDH1, #mitochondri, oxidative phosphorylation
👀oaepublish.com/articles/cdr.…
1
1
98
👏The new review explore how #tumour #heterogeneity (spatial & temporal) drives therapy resistance and how single‑cell & spatial multi‑omics can help overcome it in #Cancer #DrugResistance.
👀oaepublish.com/articles/cdr.…
1
1
49
🙌New publish in #Cancer #DrugResistance
Title: Novel N-chloroacetyl-2-pyrazoline analogs with 2-naphthyl and ferrocenyl groups: targeting #histamine receptor H1 to overcome #colorectal cancer drug resistance
#HRH1, 2-Pyrazoline, #apoptosis
2
2
73
🌟This review highlights how focused #ultrasound (US) can actively enhance glymphatic transport.
Title: Ultrasonic modulation of brain #glymphatic transport: from observations to theranostic applications
👀 oaepublish.com/articles/cdr.…
1
1
34
👉The review provides a mechanistic roadmap for using #nanomaterial-based strategies as pathway-matched, programmable interventions to overcome primary #resistance to PD-1/PD-L1 inhibitors.
PD-1/PD-L1, #immunotherapy, immune resistance, nanomaterials
👀oaepublish.com/articles/cdr.…
1
1
38
🙌The review highlights the key takeaways on ncRNAs in cancer immunotherapy.
👉Title: Roles and potential applications of non-coding #RNAs in cancer treatment with immune checkpoint inhibitors and #immunomodulatory therapies
👀oaepublish.com/articles/cdr.…
2
2
59
🌟This review systematically examines how lipid-based #nanomaterials (liposomes, lipid nanoparticles LNPs, and nanomicelles) are being engineered to overcome #drug #resistance.
Cancer resistance, lipid-based nanomaterials, nanomedicines, drug delivery
👀oaepublish.com/articles/cdr.…
1
1
59
🌟The article provides evidences for combining a #glutaminase inhibitor (CB-839) with an #HDAC inhibitor (panobinostat) to combat multiple myeloma (#MM), including bortezomib-resistant disease.
Multiple myeloma, #glutaminolysis, #GLS1, HDAC inhibitor
👀oaepublish.com/articles/cdr.…
1
1
90
🙌This comprehensive review systematically dissects the mechanisms of resistance to three novel #drug classes that have transformed multiple #myeloma (#MM) treatment in recent years.
#CAR-T cells, #SINE, #selinexor
👀oaepublish.com/articles/cdr.…
1
2
312
🙌This article presents a multi-omics framework that redefines patient stratification in acute myeloid leukemia (#AML) and offers mechanism-driven combination strategies to tackle #Venetoclax resistance.
👀oaepublish.com/articles/cdr.…
1
1
54
🙌The new publish provides a systematic synthesis of the evolving #immunotherapy landscape in malignant pleural mesothelioma (#MPM) in #Cancer #DrugResistance.
✍️Immunotherapy resistance and strategies in malignant pleural mesothelioma
👀oaepublish.com/articles/cdr.…
57
🙌The Original Article introducing a novel strategy to tackle multidrug resistance (#MDR) in cancer using conjugated oligoelectrolytes in #Cancer #DrugResistance.
👀Read: oaepublish.com/articles/cdr.…
1
2
49
🙌The review provides a timely and in-depth look at how non-coding RNAs, particularly #microRNAs (miRNAs) and circular RNAs (#circRNAs), are reshaping our understanding of breast cancer (#BC) biology and treatment.
oaepublish.com/articles/cdr.…
1
1
37
🙌This review explores how six key post-translational modifications (#PTMs) of #EGFR—collectively regulate its #signaling, stability, and trafficking.
✍️Title: From EGFR PTM network to #TKI resistance: spatial subtypes and targeting in lung cancer
oaepublish.com/articles/cdr.…
3
4
153
🙌This review provides an in-depth analysis of the current landscape of #TROP2-directed antibody-drug conjugates (#ADCs).
🌟ADC resistance, TROP2, #breast cancer, ovarian carcinoma
👀oaepublish.com/articles/cdr.…
1
1
74